| |
| |
|
| Insider
Information: |
Evnin Anthony B |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
12 |
|
| Direct
Shares |
256,515 |
|
|
Indirect Shares
|
17,979,070 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$641,597,267 |
|
|
| Total
Shares |
18,235,585 |
|
|
| Total
Value |
$641,597,267 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 118.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Renovis Inc |
RNVS |
Director |
2008-05-02 |
0 |
2008-05-02 |
0 |
Premium* |
|
|
OTIX GLOBAL INC |
OTIX |
Director |
2004-03-11 |
33,202 |
2004-03-11 |
0 |
Premium* |
|
|
Icagen Inc |
ICGN |
Director |
2011-09-02 |
7,910 |
2011-09-02 |
0 |
Premium* |
|
|
Coley Pharmaceutical Group, Inc. |
COLY |
Director, 10% Owner |
2005-08-15 |
0 |
2005-08-15 |
50,439 |
Premium* |
|
|
Viracta Therapeutics Ord Shs |
VIRX |
Director |
2005-09-30 |
0 |
2005-09-30 |
24,409 |
Premium* |
|
|
Infinity Pharmaceuticals Inc |
INFI |
|
2022-06-16 |
215,403 |
2014-09-30 |
0 |
Premium* |
|
|
Pharmos Corp |
PARS |
Director, 10% Owner |
2006-10-25 |
0 |
2009-05-08 |
9,665,196 |
Premium* |
|
|
Aveo Pharmaceuticals Inc |
AVEO |
Director |
2023-01-19 |
0 |
2018-11-21 |
109 |
Premium* |
|
|
Acceleron Pharma Inc |
XLRN |
Director |
|
0 |
2013-09-24 |
2,496,152 |
Premium* |
|
|
Juno Therapeutics, Inc. |
JUNO |
Director |
2018-02-14 |
0 |
2015-07-27 |
0 |
Premium* |
|
|
Cantel Medical Corp |
CMN |
Director |
2021-06-02 |
0 |
2017-01-05 |
0 |
Premium* |
|
|
Constellation Pharmaceuticals Inc |
CNST |
Director |
2018-07-23 |
0 |
2019-12-13 |
5,742,765 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
106 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| INFI |
Infinity Pharmaceuticals ... |
Director |
– • – |
2013-11-27 |
4 |
S |
$14.56 |
$17,472 |
I/I |
(1,200) |
130,207 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
Director |
– • – |
2013-12-02 |
4 |
S |
$14.56 |
$258,527 |
I/I |
(17,756) |
112,451 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
Director |
– • – |
2014-09-30 |
4 |
S |
$13.56 |
$1,525,229 |
I/I |
(112,451) |
0 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
Director |
– • – |
2014-10-03 |
4 |
OE |
$11.85 |
$307,765 |
D/D |
24,500 |
91,900 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
Director |
– • – |
2015-09-01 |
4 |
A |
$8.60 |
$17,492 |
D/D |
2,034 |
93,934 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
Director |
– • – |
2016-06-17 |
4 |
A |
$1.52 |
$19,999 |
D/D |
13,157 |
107,091 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
Director |
– • – |
2017-05-25 |
4 |
A |
$1.74 |
$20,000 |
D/D |
11,494 |
118,585 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
Director |
– • – |
2018-06-12 |
4 |
A |
$1.75 |
$19,999 |
D/D |
11,428 |
130,013 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
Director |
– • – |
2019-06-13 |
4 |
A |
$1.60 |
$21,000 |
D/D |
13,125 |
143,138 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
Director |
– • – |
2020-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
22,826 |
165,964 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
|
• • – |
2021-06-10 |
4 |
A |
$3.43 |
$10,499 |
D/D |
3,061 |
169,025 |
0 |
- |
|
| INFI |
Infinity Pharmaceuticals ... |
|
• • – |
2022-06-16 |
4 |
A |
$0.68 |
$31,491 |
D/D |
46,378 |
215,403 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2014-12-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
75,000 |
|
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,749,999 |
1,749,999 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2015-06-17 |
4 |
AS |
$51.59 |
$15,914,906 |
I/I |
(300,000) |
1,449,999 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2015-06-18 |
4 |
AS |
$52.07 |
$14,932,567 |
I/I |
(283,333) |
1,166,666 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2015-06-25 |
4 |
AS |
$48.39 |
$14,739,506 |
I/I |
(300,000) |
866,666 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2015-06-26 |
4 |
AS |
$46.57 |
$13,325,976 |
I/I |
(283,333) |
583,333 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2015-07-27 |
4 |
AS |
$47.82 |
$10,907,594 |
I/I |
(227,354) |
0 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2015-12-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
65,000 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2016-03-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
15,000 |
50,000 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2016-03-28 |
4 |
B |
$36.22 |
$292,662 |
D/D |
8,000 |
58,000 |
2.39 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2016-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
364 |
58,364 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2016-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
363 |
58,727 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
Director |
– • – |
2016-08-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,937 |
47,790 |
0 |
- |
|
106 Records found
|
|
Page 3 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
